Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma
Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.
Frederick Locke, MD, Moffitt Cancer Center, discusses the interim results of the phase II pivotal ZUMA-1 trial of the anti-CD19 CAR T-cell therapy KTE-C19 for patients with refractory aggressive non-Hodgkin's lymphoma.
The ZUMA-1 study looked at KTE-C19 for patients with lymphoma that was chemotherapy-refractory or following relapse within 12 months of an autologous transplant. These patients were heavily pretreated with a median of 3 prior treatments but could have received as many as 12 treatment. Of the 111 patients enrolled 101 received therapy. At the time of this interim report, there were 93 patients who had at least 1 month of follow-up. There were 62 patients with ≥3 months of follow-up.
Of the 93 patients, there was a 53% overall response rate (ORR) and a 38% complete response (CR) rate. In those with ≥3 months follow-up, the ORR was 79% and the CR rate was 52%. In those relapsing post transplant (n = 12), the CR was 75%. In those refractory to ≥2 therapies (n = 49), the CR rate was 47%.
<<<
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025